Beyond lipids - The role of the endothelium in coronary artery disease

Atherosclerosis

Volumn 147, Issue SUPPL. 1, 1999, Pages

  Aengevaeren, Wim R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Endothelial dysfunction; Plaque stability; Statins

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ANGINA PECTORIS; ARTERY ENDOTHELIUM; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG MECHANISM; HEART MUSCLE PERFUSION; HUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; PRAVASTATIN;

EID: 0032859091     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00250-6     Document Type: Conference Paper

References (43)

1. Jukema J.W., Brunschke A., van Boven A.J. et al. Effect of lipid lowering by pravastatin on the progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540.
2. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5.
3. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.
4. Pitt B., Mancini G.B., Ellis S.G. et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cardiol. 26:1995;1133-1139.
5. Gotto A.M. Jr The Lipoprotein and Coronary Atherosclerosis Study (LCAS) in context: assessing the benefits of lipid-lowering therapy. Am. J. Cardiol. 82:1998;1M.
6. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
7. Davignon J. The pleiotropic effects of drugs affecting lipid metabolism. Jaciotot B., Mathe D., Fruchart J.-C. Atherosclerosis XI. 1998;63-77 Elsevier Science, Singapore.
8. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J. Am. Med. Assoc. 279:1998;1643-1650.
9. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
10. Celermajer D.S. Endothelial dysfunction: does it matter? Is it reversible? J. Am. Coll. Cardiol. 30:1997;325-333.
11. Cooke J.P., Tsao P.S. Is NO an endogenous antiatherogenic molecule? Arterioscler. Thromb. 14:1994;653-655.
12. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
13. Celermajer D.S., Sorenson K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
14. Treasure C.B., Manoukian S.V., Klein J.L. et al. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ. Res. 71:1992;776-781.
15. Joannides R., Haefeli W.E., Linder L. et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 91:1995;1314-1319.
16. Anderson T.J., Uehata A., Gerhard M.D. et al. Close relationship of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26:1995;1235-1241.
17. Celermajer D.S., Sorenson K.E., Spiegelhalter D.J. et al. Ageing is associated with endothelial dysfunction in healthy men years before the age related decline in women. J. Am. Coll. Cardiol. 24:1994;471-476.
18. Cosentino F., Luscher T.F. Endothelial dysfunction in diabetes mellitus. J. Cardiovasc. Pharmacol. 32(Suppl 3):1998;S54-S61.
19. Lentz S.R. Homocysteine and vascular dysfunction. Life Sci. 61:1997;1205-1215.
20. Sellke F.W., Armstrong M.L., Harrison D.G. Endothelial-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 81:1990;1586-1593.
21. Zeiher A.M., Schachlinger V., Hohnloser S.H. et al. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 89:1994;2525-2532.
22. Ludmer P.L., Selwyn A.P., Shook T.L. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315:1986;1046-1051.
23. Gordon J.B., Ganz P., Nabel E.G. et al. Atherosclerosis and endothelial function influence the coronary vasomotor response to exercise. J. Clin. Invest. 83:1989;1946-1952.
24. Egashira K., Hirooka Y., Kai H. et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
25. Gould K.L., Martucci J.P., Goldberg D.I. et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential non-invasive marker of healing coronary endothelium. Circulation. 89:1994;1530-1538.
26. Eichstadt H.W., Eskötter H., Hoffman I. et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am. J. Cardiol. 76:1995;122A-125A.
27. Aengevaeren W.R.M., Kroon A.A., Stalenhoef A.F.H. et al. Low density lipoprotein-apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. The LDL-Apheresis Atherosclerosis Regression Study (LAARS). J. Am. Coll. Cardiol. 28:1996;1696-1704.
28. Tamai O., Matsuoka H., Itabe H. et al. Single LDL apheresis improves endothelial-dependent vasodilatation in hypercholesterolaemic humans. Circulation. 95:1997;76-82.
29. van Boven A.J., Jukema J.W., Zwinderman A.H. et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation. 94:1996;1503-1505.
30. Aengevaeren W.R., Uijen G.J., Jukema J.W. et al. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study. Circulation. 96:1997;429-435.
31. Dupuis J., Tardif J.-C., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes (Abstract). Am. Coll. Cardiol. 31(Suppl A):1998;891-896.
32. Dupuis J, Tardiff J-C, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischaemia and Function of the Endothelium) Trial. Circulation 1999 (in press).
33. Treasure C.B., Klien J.L., Weintraub W.S. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:1995;481-487.
34. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
35. Wood D., De Backer G., Faergeman O. et al. On behalf of the Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur. Heart J. 19:1998;1434-1503.
36. Williams J.K., Vita J.A., Manuck S.B. et al. Psychological factors impair vascular responses of coronary arteries. Circulation. 84:1991;2146-2153.
37. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol. 31:1998;684-691.
38. Lacoste L, Lam YT. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients. J Am Coll Cardiol 1996;27 (Suppl A):1045-19A.
39. Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33:1999;234-241.
40. Weissberg P. Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. Atherosclerosis 1999; 147 Suppl 1: S3-S10.
41. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
42. Sacks F.M., Pfeffer M.A., Moyle L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
43. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.